Compare NXT & KRYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NXT | KRYS |
|---|---|---|
| Founded | 2013 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.2B | 6.3B |
| IPO Year | 2023 | 2017 |
| Metric | NXT | KRYS |
|---|---|---|
| Price | $92.69 | $245.78 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 21 | 9 |
| Target Price | $91.80 | ★ $214.22 |
| AVG Volume (30 Days) | ★ 1.7M | 306.6K |
| Earning Date | 01-27-2026 | 02-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 275.72 |
| EPS | 3.85 | ★ 6.66 |
| Revenue | ★ $3,373,226,000.00 | $373,164,000.00 |
| Revenue This Year | $17.53 | $36.14 |
| Revenue Next Year | $11.36 | $41.80 |
| P/E Ratio | ★ $24.08 | $37.06 |
| Revenue Growth | 20.37 | ★ 54.51 |
| 52 Week Low | $36.06 | $122.80 |
| 52 Week High | $112.74 | $265.92 |
| Indicator | NXT | KRYS |
|---|---|---|
| Relative Strength Index (RSI) | 55.00 | 60.92 |
| Support Level | $86.64 | $231.69 |
| Resistance Level | $92.90 | $256.00 |
| Average True Range (ATR) | 3.99 | 6.63 |
| MACD | 0.23 | -1.14 |
| Stochastic Oscillator | 73.81 | 53.92 |
Nextracker (and its subsidiaries) is a leading provider of intelligent, integrated solar tracker and software solutions used in utility-scale and distributed generation solar projects around the world. Nextracker's products enable solar panels in utility-scale power plants to follow the sun's movement across the sky and optimize plant performance. Nextracker has operations in the United States, Mexico, Spain and other countries in Europe, India, Australia, the Middle East, Africa, and Brazil.
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.